

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LUPIN LTD. AND LUPIN PHARMACEUTICALS INC.,

Petitioner

v.

HORIZON THERAPEUTICS, LLC,

Patent Owner

Case IPR2017-01160

Patent 9,326,966

**PATENT OWNER HORIZON THERAPEUTICS, LLC'S
PRELIMINARY RESPONSE**

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	BACKGROUND	4
	A. Related Patents and IPR Proceedings	4
	B. Technical Background on Treatment of UCDs	7
	C. Overview of the '966 Patent	9
III.	LEVEL OF ORDINARY SKILL IN THE ART	12
IV.	CLAIM INTERPRETATION.....	14
	A. “upper limit of normal”	15
	B. “the subject,” “the patient,” “the pediatric subject,” and “the adult subject”	15
V.	THE PETITION FAILS TO DEMONSTRATE A REASONABLE LIKELIHOOD THAT THE CHALLENGED CLAIMS ARE OBVIOUS	17
	A. A POSA Would Not Have Been Motivated to Increase the Dosage of Glycerol Phenylbutyrate Based on Normal Plasma Ammonia Levels	17
	1. The '859 Publication and the Prior Art as a Whole Taught That Normal Plasma Ammonia Levels Were Acceptable	17
	2. The Potential Variability of Normal Plasma Ammonia Levels Would Not Have Motivated a POSA to Increase the Dosage of Glycerol Phenylbutyrate	23
	3. Lupin’s Obviousness Analysis Hinges on Dr. Vaux’s Conclusory and Unsupported Testimony	26
	B. Lupin Has Failed to Demonstrate that a POSA Would Have Combined the Prior Art	30
	1. Simell Concerns the Dosing of Different Drugs for a Different Condition Than the '859 Publication.....	30
	2. Simell and Blau Do Not Address the Use of Normal Fasting Plasma Ammonia Levels to Treat UCDs.....	34
	3. Simell and Blau Fail to Cure the Deficiencies of the '859 Publication	36
	C. The Petition Fails to Demonstrate a Reasonable Expectation of Success	37

D.	Lupin has Not Demonstrated That Dependent Claims 4, 7, 10 or 13 are Obvious Over the Prior Art.....	38
VI.	CONCLUSION.....	40

TABLE OF AUTHORITIES

Cases

<i>Allergan, Inc. v. Sandoz, Inc.</i> , 726 F.3d 1286 (Fed. Cir. 2013)	29
<i>Alza Corp. v. Mylan Labs, Inc.</i> , 464 F.3d 1286 (Fed. Cir. 2006)	29
<i>Ashland Oil, Inc. v. Delta Resins & Refractories, Inc.</i> , 776 F.2d 281 (Fed. Cir. 1985)	27, 30
<i>Broadcom Corp. v. Emulex Corp.</i> , 732 F.3d 1325 (Fed. Cir. 2013)	37
<i>C.R. Bard, Inc. v. Med. Components, Inc.</i> , IPR2015-01660 (P.T.A.B. Feb. 9, 2016)	28
<i>Catalina Mktg. Int'l v. Coolsavings.com, Inc.</i> , 289 F.3d 801 (Fed. Cir. 2002)	16
<i>Disney Enter., Inc. v. Kappos</i> , 923 F. Supp. 2d 788 (E.D. Va. 2013)	21
<i>Env'tl. Designs, Inc. v. Union Oil Co.</i> , 713 F.2d 693 (Fed. Cir. 1983)	13
<i>Hospitality Core Services LLC v. Nomadix, Inc.</i> , IPR2016-00052, 2016 WL 2909164 (P.T.A.B. Apr. 27, 2016)	14
<i>In re Cyclobenzaprine Extended-Release Patent Litigation</i> , 676 F.3d 1063 (Fed. Cir. 2012)	37
<i>In re Kahn</i> , 441 F.3d 977 (Fed. Cir. 2006)	29
<i>In re Paulsen</i> , 30 F.3d 1475 (Fed. Cir. 1994)	15
<i>In re Van Geuns</i> , 988 F.2d 1181 (Fed. Cir. 1993)	15
<i>In re Wilson</i> , 311 F.2d 266 (C.C.P.A. 1962)	21
<i>Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd.</i> , 821 F.3d 1359 (Fed. Cir. 2016)	3

Kinetic Techs., Inc. v. Skyworks Solutions, Inc.,
IPR2014-00529 (P.T.A.B. Sept. 23, 2014) 33

Leo Pharm. Prods. Ltd. v. Rea,
726 F.3d 1346 (Fed. Cir. 2013) 18

Pitney Bowes, Inc. v. Hewlett-Packard Co.,
182 F.3d 1298 (Fed. Cir. 1999) 16

Verlander v. Garner,
348 F.3d 1335 (Fed. Cir. 2003) 28

Zimmer Biomet Holdings, Inc. v. Four Mile Bay, LLC,
IPR2016-00011 (P.T.A.B. Apr. 1, 2016) 28

Statutes

35 U.S.C. § 103 17

35 U.S.C. § 253(a) 1

35 U.S.C. § 313 1

Regulations

37 C.F.R. § 42 6, 41

37 C.F.R. § 42.104(b)(4) 3

37 C.F.R. § 42.107 1

37 C.F.R. § 42.108(c) 6, 27, 31

37 C.F.R. § 42.22(a)(2) 3

37 C.F.R. § 42.5(b) 6

37 C.F.R. § 42.65(a) 26, 30, 35

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.